medpagetoday.com
Jan 11, 2025, 09:17
Neoadjuvant Nivo+ Ipi vs ChT in Resectable NSCLC
Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared on X:
“Neoadjuvant Nivo+ Ipi vs ChT in Resectable NSCLC (CM816) Better in terms of pCR, 3y-EFS, and OS BUT The rate of surgery cancellations due to early progression is 16%. ( Nivo+ChT: 6.7%). While pseudoprogression is a factor, such high early progression rates may prevent Nivo+Ipi from routine use.”
Authors: Mark M. Awad, Patrick M. Forde, Nicolas Girard, Jonathan Spicer, Changli Wang, Shun Lu, Tetsuya Mitsudomi, Enriqueta Felip, Stephen R. Broderick, Scott J. Swanson, Julie Brahmer, Keith Kerr, Gene B. Saylors, Ke-Neng Chen, Vishwanath Gharpure, Jaclyn Neely, David Balli, Nan Hu, and Mariano Provencio Pulla.
cancer
Changli Wang
David Balli
Enriqueta Felip
Gene B. Saylors
Jaclyn Neely
Jonathan Spicer
Julie Brahmer
Ke-Neng Chen
Keith Kerr
Mariano Provencio Pulla
Mark M. Awad
Nan Hu
Nicolas Girard
OncoDaily
Oncology
Patrick M Forde
Scott J. Swanson
Shun Lu
Stephen R Broderick
Tetsuya Mitsudomi
Vishwanath Gharpure
Yakup Ergün
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 11, 2025, 09:17
Jan 11, 2025, 09:00
Jan 11, 2025, 08:55
Jan 11, 2025, 08:44
Jan 11, 2025, 08:44
Jan 11, 2025, 08:36